A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Hummingbird Bioscience
Hummingbird Bioscience
Maia Biotechnology
KaliVir Immunotherapeutics
Eli Lilly and Company
AstraZeneca
Neonc Technologies, Inc.
Onchilles Pharma Inc
Ocellaris Pharma, Inc.
Maia Biotechnology
Inhibrx Biosciences, Inc
TScan Therapeutics, Inc.
Numab Therapeutics AG
Revolution Medicines, Inc.
Creative Biosciences (Guangzhou) Co., Ltd.
Intensity Therapeutics, Inc.
Carisma Therapeutics Inc
Advaxis, Inc.
Advaxis, Inc.
Pfizer
Sinocelltech Ltd.
Fate Therapeutics
Revolution Medicines, Inc.
Seagen Inc.
Fate Therapeutics
Rain Oncology Inc
Amgen
Revolution Medicines, Inc.
Tarveda Therapeutics
MacroGenics
Takeda
SpeciCare
Celgene
Lumos Pharma
Hoffmann-La Roche
Celgene
Takeda
Merck Sharp & Dohme LLC
Sanofi
Eli Lilly and Company
Infinity Pharmaceuticals, Inc.
Pfizer
Axelar AB
Pharmacyclics LLC.
Pfizer
Siemens Molecular Imaging
Pharmacyclics LLC.
Eli Lilly and Company